1. Home
  2. IOVA vs AMED Comparison

IOVA vs AMED Comparison

Compare IOVA & AMED Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IOVA
  • AMED
  • Stock Information
  • Founded
  • IOVA 2007
  • AMED 1982
  • Country
  • IOVA United States
  • AMED United States
  • Employees
  • IOVA N/A
  • AMED N/A
  • Industry
  • IOVA Biotechnology: Biological Products (No Diagnostic Substances)
  • AMED Medical/Nursing Services
  • Sector
  • IOVA Health Care
  • AMED Health Care
  • Exchange
  • IOVA Nasdaq
  • AMED Nasdaq
  • Market Cap
  • IOVA 2.6B
  • AMED 2.8B
  • IPO Year
  • IOVA N/A
  • AMED N/A
  • Fundamental
  • Price
  • IOVA $5.91
  • AMED $91.91
  • Analyst Decision
  • IOVA Strong Buy
  • AMED Hold
  • Analyst Count
  • IOVA 9
  • AMED 5
  • Target Price
  • IOVA $23.33
  • AMED $100.67
  • AVG Volume (30 Days)
  • IOVA 9.1M
  • AMED 580.2K
  • Earning Date
  • IOVA 02-26-2025
  • AMED 02-19-2025
  • Dividend Yield
  • IOVA N/A
  • AMED N/A
  • EPS Growth
  • IOVA N/A
  • AMED 3058.49
  • EPS
  • IOVA N/A
  • AMED 2.52
  • Revenue
  • IOVA $90,858,000.00
  • AMED $2,321,060,000.00
  • Revenue This Year
  • IOVA $13,758.71
  • AMED $7.09
  • Revenue Next Year
  • IOVA $171.20
  • AMED $5.14
  • P/E Ratio
  • IOVA N/A
  • AMED $36.48
  • Revenue Growth
  • IOVA 12751.20
  • AMED 4.19
  • 52 Week Low
  • IOVA $5.62
  • AMED $82.15
  • 52 Week High
  • IOVA $18.33
  • AMED $98.95
  • Technical
  • Relative Strength Index (RSI)
  • IOVA 28.87
  • AMED 65.93
  • Support Level
  • IOVA $5.62
  • AMED $91.56
  • Resistance Level
  • IOVA $6.44
  • AMED $92.37
  • Average True Range (ATR)
  • IOVA 0.45
  • AMED 0.75
  • MACD
  • IOVA -0.10
  • AMED 0.32
  • Stochastic Oscillator
  • IOVA 11.46
  • AMED 83.44

About IOVA Iovance Biotherapeutics Inc.

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

About AMED Amedisys Inc

Amedisys Inc is a healthcare services company in the United States. The company brings healthcare to the home through the provision of home healthcare services, hospice services, high acuity care segment, and personal care services. The Home Health Segment provides skilled nurses, therapists, and aids to patients' homes throughout the United States, Hospice segment operates many centers designed to provide comfort and support for terminally ill patients, Personal Care Segment provides individuals with assistance in their daily living activities and High acuity care segment can deliver the essential elements of inpatient hospital, SNF care, and palliative care to patients in their homes. A majority of the company's revenue is derived from the Home Health segment.

Share on Social Networks: